CLINICAL_TRIALS
trial_result
· 2013-10-17
Clinical Trial Update: Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients [Phase 3]
Summary
A Phase 3 trial comparing two glatiramer acetate formulations in relapsing-remitting multiple sclerosis completed with results posted in 2013.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Teva Neuroscience, Inc. | Conditions: Multiple Sclerosis | Phase 3 | Status: COMPLETED | Results posted: 2013-10-17